Evidence mapPaperPMID 41402339Full record

Reviewnpj aging2025

Mitochondrial dysfunction in cellular senescence: a bridge to neurodegenerative disease.

Adam J Hruby, Ryo Higuchi-Sanabria

Abstract readReview
In one paragraph

Review in npj aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Journal of microbiology and biotechnology · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Polyphenol-Rich Extracts fromAntioxidants (Basel, Switzerland) · 2026
    Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Adam J HrubyLeonard Davis School of Gerontology, University of Southern California, Los Angeles, CA, USA. ahruby@usc.edu.
Ryo Higuchi-SanabriaLeonard Davis School of Gerontology, University of Southern California, Los Angeles, CA, USA. ryo.sanabria@usc.edu.

Funding

When actin’s not actin like actin: Nuclear actin impacts transcription and agingR01AG079806 · UNIVERSITY OF SOUTHERN CALIFORNIA · 2025 to 2025
$632k
USC-Buck Geroscience Training in the Biology of AgingT32AG052374 · UNIVERSITY OF SOUTHERN CALIFORNIA · 2025 to 2025
$258k
Larry L. Hillblom Foundation 2022-A-010-SUPNational Institute of Aging T32AG052374National Science Foundation Graduate Research Fellowship Program DGE-1842487NIA NIH HHS R01 AG079806NIA NIH HHS R01AG079806NIA NIH HHS T32 AG052374
6 · The paper itself

Abstract

Senescent cells, characterized by a state of irreversible proliferative arrest and inflammatory profile, have emerged as drivers of age-related decline. Growing evidence suggests that alterations in mitochondrial function and morphology play a key role in the induction and maintenance of senescence, as well as in promotion of the proinflammatory senescence-associated secretory phenotype (SASP). In this review, we seek to survey the relationship between mitochondrial dysfunction and senescence, focusing on the consequences of changes in oxidative phosphorylation efficiency, calcium handling, mitochondrial metabolites, mitochondrial dynamics and quality control, and release of damage-associated molecular patterns. We first describe these changes before illustrating the pathways and mechanisms through which mitochondrial dysfunction results in cell cycle arrest and the SASP. Lastly, we showcase evidence relating cellular senescence to neurodegenerative disease and propose that mitochondrial dysfunction may act as a bridge between the two.

Identifiers

PMID41402339
PMCPMC12708852

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.